Q-omics provides the consensus-scored MED29 profile across patient tissues and cancer cell-line models. MED29 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, MED29 is differentially expressed in 10, with the highest sampling consensus in HNSC. Additionally, MED29 protein abundance shows 22,265 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight KIRC, HNSC, and LSCC as cancer lineages where MED29 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MED29 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MED29 survival associations across molecular data types. MED29 RNA expression shows survival associations in the most cancer types (23), followed by mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MED29 RNA expression–survival associations across cancer types. High MED29 expression shows unfavorable associations in UVM and LIHC, but favorable associations in KIRC, BRCA, SCLC and UCS. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for MED29 RNA expression.
This table summarizes MED29 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 7. The strongest signals are observed in HNSC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for MED29. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MED29 shows lower tumor expression in KICH and THCA and higher tumor expression in HNSC, LIHC, KIRC and BRCA. The HNSC box plot shows higher MED29 RNA expression in tumor versus normal tissue (log2 FC = +0.612, t-test p < 0.001).
This table shows molecular features associated with MED29 in patient tissues and cancer cell lines. In patient samples, MED29 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, MED29 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and BLOOD_Leukemia.
